Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess the BRCA1/2m Prevalence, Treatment Approaches and Outcomes in HER2-negative High-risk Early Breast Cancer Patients in Russia

NCT05939128 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05939128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05939128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess the BRCA1/2m Prevalence, Treatment Approaches and Outcomes in HER2-negative High-risk Early Breast Cancer Patients in Russia
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
June 30, 2023
Completion date
September 30, 2027
Enrollment
625 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer